News & Updates

Show Multimedia Only

Endocan, miR-221 predict development of diabetic neuropathy

09 Jan 2026 by

Endocan and miR-221 expression levels are significantly associated with development of neuropathy in patients with diabetes, indicating their potential role as biomarkers to diagnose diabetic peripheral neuropathy (DPN) at an early stage before the development of clinical manifestations, reports a study presented at ATTD-Asia 2025.

Endocan, miR-221 predict development of diabetic neuropathy

09 Jan 2026

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

09 Jan 2026

In the treatment of acute ischaemic stroke in patients with recent direct oral anticoagulant (DOAC) use, intravenous thrombolysis appears to be safe and is associated with improvements in functional outcomes, according to a study.

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

09 Jan 2026

Flu vaccination exerts no influence on PD risk

08 Jan 2026

Influenza immunization at midlife neither increases nor reduces the risk of Parkinson’s disease (PD), as shown in a study.

Flu vaccination exerts no influence on PD risk

08 Jan 2026

Topiramate tied to weight loss vs other antiseizure drugs

06 Jan 2026

Among commonly used antiseizure medications (ASMs), topiramate appears to result in weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation-only effects, reports a study. Other ASMs seem to contribute to greater weight change.

Topiramate tied to weight loss vs other antiseizure drugs

06 Jan 2026

Original New Drug Application Approvals by US FDA (16-31 December 2025)

06 Jan 2026

New drug applications approved by US FDA as of 16-31 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2025)

06 Jan 2026

Poststroke chronic vertigo and dizziness require individualized rehabilitation

03 Jan 2026 by

The significantly poorer health-related quality of life (HRQoL) in patients with chronic vertigo and dizziness compared with those without, following a stroke, necessitates systematic poststroke screening, comprehensive multidisciplinary assessment and individualized rehabilitation, according to a stroke cohort study.

Poststroke chronic vertigo and dizziness require individualized rehabilitation

03 Jan 2026

Childhood maltreatment increases schizophrenia risk 5-fold

02 Jan 2026 by

Childhood maltreatment increases the risk of schizophrenia by five-fold, attention deficit hyperactivity disorder (ADHD) by 10-fold, and major depressive disorder (MDD) by nearly two-fold. It also leaves lasting genetic markers linked to neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease, a Mendelian randomization study has shown.

Childhood maltreatment increases schizophrenia risk 5-fold

02 Jan 2026

Lubiprostone use heightens risk of headache

30 Dec 2025

Treatment with lubiprostone is associated with an increased risk of headache in adults and children, according to a recent meta-analysis.

Lubiprostone use heightens risk of headache

30 Dec 2025

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

30 Dec 2025 by

Migraine is a highly disabling neurological condition that profoundly affects patients’ quality of life (QoL) and productivity. Traditional first-line (1L) preventive treatments were not originally developed for migraine and are often limited by suboptimal efficacy and poor tolerability. In an interview with MIMS Doctor, Dr William Kingston of the Division of Neurology, Department of Medicine, Temerty School of Medicine, University of Toronto, Canada, discussed the emergence of calcitonin gene–related peptide (CGRP) inhibitors, including atogepant, as a significant breakthrough in migraine prevention, offering targeted, migraine[1]specific efficacy with improved tolerability.

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

30 Dec 2025

Impaired kidney function influences AD blood biomarkers but not dementia risk

17 Dec 2025 by

Among individuals without cognitive impairment, those with impaired kidney function exhibit increased levels of Alzheimer’s disease (AD) blood biomarkers, although they do not appear to be at increased risk of dementia compared with those who have preserved kidney function, according to new research.

Impaired kidney function influences AD blood biomarkers but not dementia risk

17 Dec 2025

News & Updates

Showing Neurology articles

Showing

Specialty:

Endocan, miR-221 predict development of diabetic neuropathy

Endocan, miR-221 predict development of diabetic neuropathy

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

Intravenous thrombolysis safe, beneficial for stroke patients with recent DOAC use

Flu vaccination exerts no influence on PD risk

Flu vaccination exerts no influence on PD risk

Topiramate tied to weight loss vs other antiseizure drugs

Topiramate tied to weight loss vs other antiseizure drugs

Original New Drug Application Approvals by US FDA (16-31 December 2025)

Original New Drug Application Approvals by US FDA (16-31 December 2025)

Poststroke chronic vertigo and dizziness require individualized rehabilitation

Poststroke chronic vertigo and dizziness require individualized rehabilitation

Childhood maltreatment increases schizophrenia risk 5-fold

Childhood maltreatment increases schizophrenia risk 5-fold

Lubiprostone use heightens risk of headache

Lubiprostone use heightens risk of headache

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

Impaired kidney function influences AD blood biomarkers but not dementia risk

Impaired kidney function influences AD blood biomarkers but not dementia risk